Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically unfavourable mutation," according to Wolfgang Brueckl, MD, of t ...

and Roche's Kadcyla (trastuzumab emtansine) – both HER2-targeting ADCs – but may raise questions about its confidence in Tukysa. That said, RemeGen and Seagen are targeting gastric ...

Trastuzumab has changed the standard of care for MBC patients who overexpress the HER2-receptor protein. In heavily pretreated patients who overexpress HER2, trastuzumab produces objective ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...